| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 60.2 | 47.2 |
| Net income | 1.4 | -18.4 |
| EPS (diluted, $ a share) | $0.00 | $-0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +27.4% |
|---|---|
| Operating margin | 9.6% |
10-Q filed with the SEC, NASDAQ: GERN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Geron Corp: key numbers
- Share price
- $0.9419Close, Nov 16
- Market cap
- $607M
- Shares outstanding
- 644.24MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Geron Corp
All →Geron Financial Results
Geron Corporation reported third quarter 2026 financial results, highlighted by $60.1 million in RYTELO net product revenue, a 5% increase over the prior quarter. The company reiterated its full-year RYTELO revenue guidance at the mid-to-high end of $220-$240 million and initiated a gated commercial launch in Europe, with availability expected in Germany by year-end.
- Term
- Q3 2026
“Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.”
Harout Semerjian, President and Chief Executive Officer of Geron
Geron Clinical Trial Data
Geron Corporation is discontinuing its Phase 3 IMpactMF clinical trial of imetelstat in relapsed/refractory myelofibrosis based on a recommendation from an independent Data Monitoring Committee. The committee advised that the trial was unlikely to meet its primary endpoint of overall survival, although no new safety signals were observed.